Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov-Dec;44(6):792-7.
doi: 10.4103/0253-7613.103304.

Cutaneous adverse drug reaction profile in a tertiary care out patient setting in eastern India

Abanti Saha  1 , Nilay Kanti Das, Avijit Hazra, Ramesh Chandra Gharami, Satyendra Nath Chowdhury, Pijush Kanti Datta
Affiliations

Cutaneous adverse drug reaction profile in a tertiary care out patient setting in eastern India

Abanti Saha et al. Indian J Pharmacol. 2012 Nov-Dec.

Abstract

Background: Cutaneous adverse drug reactions (CADR) are the most frequent of all manifestations of drug sensitivity and manifest with varied and diverse morphology.

Aims: To study the prevalence and clinical spectrum of CADR among patients attending outpatient department (OPD) in a tertiary care hospital.

Materials and methods: An observational study was undertaken over a 1-year period in dermatology OPD of a tertiary care teaching hospital in Eastern India. Patients presenting with suspected drug-related cutaneous lesions were included if drug identity could be ascertained. Clinical profiling was done. Drug history was recorded in a format specified in Indian National Pharmacovigilance Programme and causality assessment carried out as per World Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria.

Results: Commonest CADR in our study was morbilliform eruption (30.18%), followed by fixed drug eruption (24.52%), Stevens-Johnson syndrome (SJS)-Toxic epidermal necrolysis (TEN) and overlap of two (24.50%), exfoliative dermatitis (7.54%), urticaria (5.6%), phototoxic drug reaction (3.8%), pityriasis rosea-like eruptions (1.89%), and severe mucositis (1.80%). Drugs implicated were sulfonamides (17%), fixed-dose combinations of fluoroquinolones with nitroimidazoles (11.30%), analgesics (11.30%), antiepileptics (11.30%), beta-lactam antibiotics (9.40%), fluoroquinolones alone (7.50%), allopurinol (7.50%), and azithromycin (5.70%). Reaction latency varied from 1 to 43 days. Causality assessment was certain and probable for 18.9% and 41.5% of the reactions, respectively, and reactions were serious in 33.96% (95% confidence interval 21.21-46.71%).

Conclusions: Cutaneous adverse drug reaction profile in this study is similar in many ways to studies conducted earlier in India. Incidence of life-threatening reactions like SJS-TEN was higher compared with studies conducted abroad. Reaction time and lesion patterns are helpful in identifying an offending drug in the setting of multiple drug therapy.

Keywords: Causality assessment; cutaneous adverse drug reaction; dermatologic pharmacology; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

Conflicting Interest: No.

Figures

Figure 1
Figure 1
Indication for drug intake in the major cutaneous drug reaction categories
See this image and copyright information in PMC

References

    1. Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53:2–8. - PMC - PubMed
    1. Sengupta SR, Das NK. Cutaneous adverse drug reaction to systemic drugs: Recent updates. In: Ghosh S, editor. Recent Advances in Dermatology. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2004. pp. 88–114.
    1. Uppsala: The Uppsala Monitoring Centre; 2005. [Last accessed 2010 Apr 7]. The use of the WHO-UMC system for standardized case causality assessment [monograph on the Internet] Available from: http://www.who-umc.org/graphics/4409.pdf .
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ. 2004;329:15–9. - PMC - PubMed
    1. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001;53:357–79. - PubMed